Zacks Research Issues Positive Forecast for SRPT Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at Zacks Research lifted their Q2 2026 earnings per share estimates for Sarepta Therapeutics in a report released on Monday, October 21st. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $3.32 per share for the quarter, up from their prior estimate of $3.20. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.45 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q3 2026 earnings at $3.31 EPS and FY2026 earnings at $12.86 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same quarter in the prior year, the business posted ($0.27) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 38.9% on a year-over-year basis.

A number of other research analysts also recently commented on SRPT. Jefferies Financial Group started coverage on Sarepta Therapeutics in a report on Monday. They set a “buy” rating and a $165.00 target price on the stock. Piper Sandler reduced their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 14th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $152.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 20th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday. Two equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $182.95.

Sarepta Therapeutics Trading Up 1.1 %

NASDAQ:SRPT opened at $129.88 on Tuesday. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The business’s 50 day moving average is $128.87 and its two-hundred day moving average is $132.42. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $173.25. The company has a market cap of $12.28 billion, a PE ratio of 1,180.73 and a beta of 0.82.

Insider Activity at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Michael Andrew Chambers purchased 37,038 shares of the stock in a transaction dated Friday, August 16th. The shares were bought at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now owns 284,034 shares in the company, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently modified their holdings of SRPT. GAMMA Investing LLC increased its position in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares during the period. Mather Group LLC. bought a new stake in shares of Sarepta Therapeutics during the 1st quarter worth $28,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Sarepta Therapeutics by 100.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,996 shares of the biotechnology company’s stock worth $647,000 after acquiring an additional 2,504 shares in the last quarter. Hudson Capital Management LLC bought a new stake in shares of Sarepta Therapeutics during the 1st quarter worth $220,000. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Sarepta Therapeutics by 8.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 5,243 shares of the biotechnology company’s stock worth $679,000 after acquiring an additional 418 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.